StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3099% above fair value
$170.26+2.68 (+1.60%)

Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%

Gilead Sciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Gilead Sciences's price to sales ratio was 6.9× on Nov 11, 2026, against 5.4× a year earlier. Over the last 5 years it ranged from 2.7× to 7.0×, with a median of 3.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.9×+1.7
2025Dec 31, 20255.2×+1.2
2024Dec 31, 20244.1×+0.4
2023Dec 29, 20233.7×−0.3
2022Dec 30, 20224.0×+0.7
2021Dec 31, 20213.3×+0.2
2020Dec 31, 20203.2×−0.5
2019Dec 31, 20193.7×+0.0
2018Dec 31, 20183.6×+0.2
2017Dec 29, 20173.4×+0.4
2016Dec 30, 20163.0×−1.7
2015Dec 31, 20154.7×−2.2
2014Dec 31, 20146.9×−3.9
2013Dec 31, 201310.8×+4.8
2012Dec 31, 20126.0×+2.2
2011Dec 30, 20113.8×−0.1
2010Dec 31, 20103.9×−2.2
2009Dec 31, 20096.1×–

More Gilead Sciences figures

See a number that looks wrong?